RenovoRx(RNXT.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
RenovoRx
RNXT.US
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.
1.813 T
RNXT.USMarket value -Rank by Market Cap -/-

Financial Score

19/05/2026 Update
C
BiotechnologyIndustry
Industry Ranking159/386
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-100.47%E
    • Profit Margin-823.98%E
    • Gross Margin85.08%A
  • Growth ScoreB
    • Revenue YoY520.42%A
    • Net Profit YoY-20.78%D
    • Total Assets YoY-12.80%E
    • Net Assets YoY-14.38%E
  • Cash ScoreB
    • Cash Flow Margin92.11%C
    • OCF YoY520.42%A
  • Operating ScoreE
    • Turnover0.1E
  • Debt ScoreA
    • Gearing Ratio19.33%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    RenovoRx (RNXT) Q1 2026 Earnings Transcript

    Motley Fool·
    US
    RNXT
    +2.15%
    US
    IXJ
    +0.98%
    US
    LABU
    +0.67%
    Motley Fool·
    US
    RNXT
    +2.15%
    US
    IXJ
    +0.98%
    US
    LABU
    +0.67%

    RenovoRx CEO, CFO to speak at Alliance Global Partners annual healthcare showcase

    PUBT·
    US
    RNXT
    +2.15%
    US
    IXJ
    +0.98%
    US
    XBI
    +0.28%
    PUBT·
    US
    RNXT
    +2.15%
    US
    IXJ
    +0.98%
    US
    XBI
    +0.28%

    RenovoRx Reports Q1 2026 Results: Full Earnings Call Transcript

    benzinga_article·
    US
    RNXT
    +2.15%
    US
    XLV
    +1.23%
    US
    XBI
    +0.28%
    benzinga_article·
    US
    RNXT
    +2.15%
    US
    XLV
    +1.23%
    US
    XBI
    +0.28%

    RenovoRx | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 563 K

    Earnings Watch·
    US
    RNXT
    +2.15%
    Earnings Watch·
    US
    RNXT
    +2.15%

    RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting

    Unusual Whales·
    US
    RNXT
    +2.15%
    US
    XLV
    +1.23%
    US
    PBE
    +0.37%
    Unusual Whales·
    US
    RNXT
    +2.15%
    US
    XLV
    +1.23%
    US
    PBE
    +0.37%
    © 2026 Longbridge｜Disclaimer